IDH2 and central nervous system cancer: According to this classification, the most critical molecular signature for these optimized categories for the prognosis and treatment stratification of diffuse gliomas is IDH mutation, and IDH-wt gliomas have a worse prognosis than IDH-mutant gliomas [4,5,6].